Answers are grounded in this paper and cite their sources.
A precise diagnosis for neuromyelitis optica spectrum disorders (NMOSD) is crucial to improve patients’ prognostic, which requires highly specific and sensitive tests. The cell-based assay with a sensitivity of 76% and specificity of 100% is the most recommended test to detect anti-aquaporin-4 antibodies (AQP4-Ab). Here, we tested four AQP4 external loop peptides (AQP4 61–70 , AQP4 131–140 , AQP4 141–150 , and AQP4 201–210 ) with an atomic force microscopy nanoimmunosensor to develop a diagnostic assay. We obtained the highest reactivity with AQP4 61–70 -nanoimunosensor. This assay was effective in detecting AQP4-Ab in sera of NMOSD patients with 100% specificity (95% CI 63.06–100), determined by the cut-off adhesion force value of 241.3 pN. NMOSD patients were successfully discriminated from a set of healthy volunteers, patients with multiple sclerosis, and AQP4-Ab-negative patients. AQP4 61–70 sensitivity was 81.25% (95% CI 56.50–99.43), slightly higher than with the CBA method. The results with the AQP4 61–70 -nanoimmunosensor indicate that the differences between NMOSD seropositive and seronegative phenotypes are related to disease-specific epitopes. The absence of AQP4-Ab in sera of NMOSD AQP4-Ab-negative patients may be interpreted by assuming the existence of another potential AQP4 peptide sequence or non-AQP4 antigens as the antibody target.
No takes yet. Share an insight, caveat, or question.
Moraes et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: